Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss (NCT04935138) | Clinical Trial Compass
TerminatedNot Applicable
Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss
Stopped: Low participation
United States78 participantsStarted 2021-06-01
Plain-language summary
The study assesses the accuracy of cell-free DNA (cfDNA) analysis in detecting whole chromosomal aneuploidies from maternal plasma of patients with early, missed miscarriage.
Who can participate
Age range18 Years – 50 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 5-20 weeks of gestation by ultrasound
* Miscarriage diagnosed by ultrasound
* Pregnancy tissue still present in utero, including an empty sac, and not completely expelled
Exclusion Criteria:
* Maternal age \< 18 years
* No visible pregnancy tissue on ultrasound
* Multiple fetal gestation (\> than singleton)
* Pregnancy was conceived using in vitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) performed on the transferred embryo
* No microarray testing is planned on the product of conception
* Previous normal non-invasive prenatal testing (NIPT) or diagnostic testing (chorionic villous sampling or amniocentesis) in the current pregnancy
* Patient unable to provide consent
What they're measuring
1
microarray analysis of products of conception (POC)